

THE RESEARCH REVIEW

School of Medicine Quarterly Newsletter



IN THIS ISSUE

NEW NIH AWARDS: MAR-MAY 2024

OTHER NEW AWARDS: MAR-MAY 2024

NEW IN RESEARCH



For more information on School of Medicine research opportunities and policies visit our web page <u>HERE</u>.



PI: Dr. Marta Rodriguez-Garcia - Biochemistry, Microbiology and Immunology



PI: Dr. Malathy Shekar-Oncology

Aging Compromises Neutrophil-Mediated Innate Protection Against HIV in the Human Female Genital Tract

Award Number: 7R01AG060801-06

To prevent HIV acquisition in women and enable medical advances, the defense mechanisms that protect the female reproductive tract (FRT) from HIV infection need to be identified. This proposed research will investigate defense mechanisms that exist in FRT neutrophils. The identification of a new form of protection against HIV in the FRT will open new pathways for the development of HIV prevention strategies for women

Elucidation of a novel transcriptional reprogramming-induced mechanism of endocrine resistance and therapeutic targeting

Award Number: 1R21CA288314-01


Endocrine therapy represents the most effective targeted therapy for estrogen receptor-positive breast cancers; however, their effectiveness is greatly limited by resistance development, toxicity and recurrence/relapse, posing a major clinical challenge. This proposal will lay the foundation for testing a new and nontoxic strategy for inhibiting tamoxifen resistant tumor growth and metastasis. In this proposal we will (1) elucidate the molecular underpinnings of a novel transcriptional reprogramming mechanism of tamoxifen resistance, (2) develop a nontoxic therapeutic strategy to overcome tamoxifen resistance, and (3) identify novel markers with diagnostic, prognostic, and/or targeted therapeutic potential.

JUNE 3, 2024 VOL. 07

NEW NIH AWARDS CONTINUED



PI: Dr. Mark Greenwald- Psuchiatru and Behavioral





PI: Jugmohit Toor- Cancer Biology

TRAIN@wayne: Translational Research in Addiction and Integrative Neuroscience

Award Number: 1T32DA060139-01

Drug use is the leading cause of preventable death in the United States. There is an urgent national need to equip the next generation of predoctoral addiction researchers with the expertise, tools, and techniques necessary to advance discovery science and accelerate development of therapeutics to address drug addiction. This grant describes a robust interdisciplinary training program, TRAIN@wayne, uniquely focused on the translational study of addiction neurobiology and exposure to state-of-the-art research methods and rigorous experimental design, complemented by robust career development and individualized mentorship.

Investigating the MAIT cell- Microbiome Relationship in Pancreatic Cancer Liver Metastasis

Award Number: 1F30CA291094-01

Gut microbiome modulation alters the repertoire of gut microbiome derived antigens that traverse from the gut to the liver and has been shown to augment anti-tumor immunitu in pancreatic cancer liver metastasis (PCLM). Mucosal associated invariant T (MAIT) cell are a unique subset of invariant T cells which can be modulated to switch from a "pro-tumor" MAIT17 phenotype (suppresses cytotoxic cells) to an "anti-tumor" MAIT1 phenotype (activates cytotoxic cells) by specific activation pathways induced by microbial derived antigens. The goal of this project is to harness the gut microbiome to modulate MAIT cells in the PCLM tumor microenvironment towards a MAIT1 phenotype to promote anti-tumor immunity and reduce PCLM tumor burden.

OTHER NEW AWARDS

INVESTIGATING THE MAIT CELL- MICROBIOME **RELATIONSHIP IN PANCREATIC CANCER LIVER METASTASIS**

PI: Dr. Qing-Sheng Mi -Department of Oncology-

ECOG-ACRIN OPERATIONS CENTER

PI: Dr. Anthony Shields-Department of Oncology-25X1N

INVOLUTION-BASED BIOMARKERS OF BREAST **CANCER RISK**

PI: Dr. Julie Boerner -Department of Oncology-25X4X

HIGH THROUGH-PUT PROFILING OF CARP-1 **REGULATED PROTEINS IN CANCER CELLS**

PI: Dr. Arun Rishi- Department of Oncology-25X51

DEVELOPMENT OF USP10 SELECTIVE INHIBITORS FOR THE TREATMENT OF FLT3-ITD AML

PI: Dr. Yubin Ge-Department of Oncology-25X53

ADVANCED WIRELESS AUGMENTED REALITY-**ENHANCED EXPOSURE THERAPY FOR** POSTTRAUMATIC STRESS DISORDER

PI: Dr. Arash Javanbakht -Department of Psychiatry-

ECOG-ACRIN OPERATIONS CENTER- CLINICAL TRIALS

PI: Dr. Anthony Shields-Department of Oncology-25X1N

IMPROVING DIAGNOSTIC ACCURACY FOR ACUTE **HEART FAILURE**

PI: Dr. Phillip Levy- Department of Emergency Medicine-25X4O

CHARACTERIZING A VHL-BASED HDAC6 PROTAC **DEGRADER, WH316**

PI: Dr. Xiaohong (Mary) Zhang-Department of Oncology-

TARGETING DNA REPAIR DEFICIENCIES IN LUNG AND PANCREATIC CANCER

PI: Dr. Stephan Patrick-Department of Oncology-



SOM RESEARCH **FACTS**

The SoM award total at this point for 2024 is \$73,207,205 and approximately 64% of the proposals submitted were awarded.

We also compared the number of proposals submitted and the number of awards received through May 2023 to this year, see below for the figures.

<u>Proposals</u>

2023 \$357,070,154/418 submitted 2024 \$277,415,543/321 submitted**

Awards

2023 \$92.317.481/252 awarded 2024 \$73,207,205/206 awarded**

**Please note that the May amounts for proposals and awards for May 2024 are being verified by OVPR and may increase after that process.

Note:

We strive to include all new awards for the quarter in the newsletter. However, if you wish to guarantee the mention of your award, please don't hesitate to send the details to us at <u>WSU-RAS@wayne.edu</u>

JUNE 3, 2024 VOL. 07

NEW IN RESEARCH


NIAID has stated they will be increasing the maximum salary and research support provided on the K99 awards for applications due on or after June 12, 2024 NOT-AI-24-038

OVPR's Research Development Office offers a variety of resources to support the research of the faculty please see the link <a href="https://here.no.nic.gov/h

See the upcoming changes that NIH has communicated are coming in regards to the application review NOT-OD-24-084 and NOT-OD-24-107

Effective immediately the NIDA will be phasing out MERIT Awards (R37) for established investigators but there are no expected changes for current grant recipients NS-24-079 This policy is being instituted to provide longer-term grant support for early-stage investigators (ESIs) NOT-DA-24-017

NIH has released the new NRSA Stipends,
Tuition/Fees and Other Budgetary Levels that are
effective for 2024. NOT-OD-24-104





NIH has communicated that they plan to implement new questions for RPPRs that will be submitted on or after October 1, 2024, which will align with the policy on Data Management and Sharing.

NOTOD-24-123

Beginning with applications submitted on or after September 25, 2024 to the NIAID, they will limit the number of predoctoral and or/postdoctoral training slots to a maximum of 8 trainee slots in any given year NOT-AI-24-052

Sponsored Program Administration has revised the "At-Risk" section of the proposal submission deadline policy to read proposals received later than noon on the sponsor's deadline day WILL NOT BE SUBMITTED TO THE SPONSOR. You may read the policy in its entirety by clicking on the link here

Effective immediately the NINDS is establishing a more stringent payline for all grant applications requesting \$500K or more in direct costs in any year in response to Parent R01 NOFOs. NOT-NS-24-079